Physician profile
Daniel K Olson
NPI 1467914515
$1,448.61
in general payments reported to CMS, 2019-2025
19 companies · $867 in 2025
The $867 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $53.82 · 2023: $57.60 · 2024: $470 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,394.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $599.65 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $231.43 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $97.48 | 2024-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $83.31 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $67.87 | 2024-2025 | |
| Novo Nordisk INC | $46.20 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $40.77 | 2024 | Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $37.71 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $36.41 | 2024 | Rexulti |
| Lundbeck LLC | $35.28 | 2024-2025 | Rexulti |
| Irhythm Technologies, INC. | $25.06 | 2024 | Zio Monitor, Zio Xt Patch |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.97 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.76 | 2023 | Lifevest |
| Phadia US INC. | $19.73 | 2025 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.22 | 2024 | Tradjenta, Jardiance |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.11 | 2022 | |
| Biomerieux INC | $15.89 | 2023 | Nephrocheck Liquid Control Kit |
| Abbott Laboratories | $14.27 | 2024 | Freestyle Libre 3 |
| Invivyd INC | $13.49 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.